Qvents

Qvents

Discussion forum for Pharma Quality events, Regulatory Actions

Warning letters, 483s, Recalls, Import Alerts, Audit observations

GMP Good Manufacturing Practices –

USFDA 21CFR PART 210—Current Good Manufacturing Practice in Manufacturing, Processing, Packing, Or Holding Of Drugs;

Inspections (GMP, Others)

Qvents compiled list of regulatory guidelines on GMP inspections from different agencies – USFDA, EMA, EDQM, WHO, PIC-S. Quick reference

Biosimilars / Biologics

USFDA: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (April 2015) USFDA: Scientific Considerations

Nitrosamines

USFDA: Guidance for Industry: Control of Nitrosamine Impurities in Human Drugs; USFDA Updates on possible

Excipients related

Excipient Risk Assessment (Europe): Guidelines of 19 March 2015 on the formalised risk assessment for

Water system

USFDA: High Purity Water System; Guide To Inspections Of High Purity Water Systems USFDA Inspection

Variations and Changes – NDAs, ANDAs,

USFDA: Changes to an Approved NDA or ANDA USFDA: Changes to an Approved NDA or

Technology Transfer

WHO TRS 1044 – Annex 4: WHO Guidelines on Technology Transfer in Pharmaceutical Manufacturing ISPE:

Storage and Distribution, Transport and

WHO TRS 1025 – Annex 7: Good Storage and Distribution Practices for Medical Products (June

Stratified Sampling – Content Unif

Refer discussions under Questions and Answers on Current Good Manufacturing Practice Regulations | Production and